Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants

Journal of Virological Methods

Volumn 221, Issue , 2015, Pages 29-38

  Thys, Kim ^a   Verhasselt, Peter ^a   Reumers, Joke ^a   Verbist, Bie M P ^b   Maes, Bart ^a   Aerssens, Jeroen ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Deep sequencing; HCV; HIV; Illumina; Massively parallel sequencing; Viral minority

Indexed keywords

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP SEQUENCING; DNA SEQUENCE; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIMIT OF DETECTION; MASSIVELY PARALLEL SEQUENCING; MEASUREMENT ACCURACY; NONHUMAN; PRIORITY JOURNAL; VIRUS DETECTION; CLASSIFICATION; EVALUATION STUDY; GENETICS; HEPACIVIRUS; HEPATITIS C; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PROCEDURES; VIROLOGY;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV; HIV INFECTIONS; HUMANS; VIROLOGY;

EID: 84928958187     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.04.022     Document Type: Article

References (53)

1. Abram M.E., Ferris A.L., Shao W., Gregory W., Hughes S.H., Alvord W.G. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 2010, 84:9864-9878. 10.1128/JVI.00915-10.
2. Asselah T., Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 31 Suppl 2011, 1:68-77. 10.1111/j.1478-3231.2010.02411.x.
3. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81:1631-1648.
4. Barzon L., Lavezzo E., Militello V., Toppo S., Palù G. Applications of next-generation sequencing technologies to diagnostic virology. Int. J. Mol. Sci. 2011, 12:7861-7884. 10.3390/ijms12117861.
5. Capobianchi M.R., Giombini E., Rozera G. Next-generation sequencing technology in clinical virology. Clin. Microbiol. Infect. 2013, 19:15-22. 10.1111/1469-0691.12056.
6. Cheval J., Sauvage V., Frangeul L., Guigon G., Dumey N., Pariente K., Rousseaux C., Dorange F., Berthet N., Brisse S., Moszer I., Bourhy H., Jean C., Lecuit M., Burguiere A., Caro V., Eloit M., Dacheux L., Manuguerra C.J. Evaluation of high-throughput sequencing for identifying known and unknown viruses in biological samples. J. Clin. Microbiol. 2011, 49:3268-3275. 10.1128/JCM.00850-11.
7. Cline J., Braman J.C., Hogrefe H.H. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res. 1996, 24:3546-3551.
8. De Wolf H., Van Marck H., Mostmans W., Thys K., Vandenbroucke I., Van Eygen V., Pattery T., Verhasselt P., Aerssens J. HIV-1 nucleotide mixture detection in the virco(®)TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing. J. Virol. Methods 2011, 175:129-132. 10.1016/j.jviromet.2011.04.023.
9. Domingo E., Sheldon J., Perales C. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 2012, 76:159-216. 10.1128/MMBR.05023-11.
10. Dumont S., Fevery B., Van den Brande K., Baumer V., Ceulemans H., DeWolf H., Stuyver L.J., Koletzki D. Development of a platform to detect drug resistance mutations in the non-structural protein region of the hepatitis C virus genotypes 1, 2, 3, and 4. J. Hepatol. 2009, 50:S124. 10.1016/S0168-8278(09)60321-4.
11. Ewing B., Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 1998, 8:186-194.
12. Fisher R., van Zyl G.U., Travers S.A., Kosakovsky Pond S.L., Engelbrech S., Murrell B., Scheffler K., Smith D. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J. Virol. 2012, 86:6231-6237. 10.1128/JVI.06541-11.
13. Flaherty P., Natsoulis G., Muralidharan O., Winters M., Buenrostro J., Bell J., Brown S., Holodniy M., Zhang N., Ji H.P. Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res. 2012, 40:e2. 10.1093/nar/gkr861.
14. Gianella S., Delport W., Pacold M.E., Jason A., Choi J.Y., Little S.J., Douglas D., Pond S.L.K., Smith D.M., Young J.A., Richman D.D., Kosakovsky Pond S.L. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J. Virol. 2011, 85:8359-8367. 10.1128/JVI.02582-10.
15. Gilles A., Meglécz E., Pech N., Ferreira S., Malausa T., Martin J.-F. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 2011, 12:245. 10.1186/1471-2164-12-245.
16. Hamady M., Walker J.J., Harris J.K., Gold N.J., Knight R. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat. Methods 2008, 5:2007-2009. 10.1038/NMETH.1184.
17. Hedskog C., Mild M., Jernberg J., Sherwood E., Bratt G., Leitner T., Lundeberg J., Andersson B., Albert J. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 2010, 5:e11345. 10.1371/journal.pone.0011345.
18. Huse S.M., Huber J.A., Morrison H.G., Sogin M.L., Welch D.M. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol. 2007, 8:R143. 10.1186/gb-2007-8-7-r143.
19. Jabara C.B., Jones C.D., Roach J., Anderson J.A., Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 2011, 108:20166-20171. 10.1073/pnas.1110064108.
20. Johnson J.A., Li J.-F., Wei X., Lipscomb J., Irlbeck D., Craig C., Smith A., Bennett D.E., Monsour M., Sandstrom P., Lanier E.R., Heneine W. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 2008, 5:e158. 10.1371/journal.pmed.0050158.
21. Johnson V., a, Calvez V., Günthard H.F., Paredes R., Pillay D., Shafer R., Wensing A.M., Richman D.D. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 2011, 19:156-164.
22. Krieger N., Lohmann V., Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 2001, 75:4614-4624. 10.1128/JVI.75.10.4614.
23. Lauck M., Alvarado-Mora M.V., Becker E., Bhattacharya aD., Striker R., Hughes A.L., Carrilho F.J., O'Connor D.H., Pinho J.R.R. Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. J. Virol. 2012, 86:3952-3960. 10.1128/JVI.06627-11.
24. Le T., Chiarella J., Simen B.B., Hanczaruk B., Egholm M., Marie L., Dieckhaus K., Rosen M.I., Kozal M.J., Landry M.L. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009, 4:e6079. 10.1371/journal.pone.0006079.
25. Li J.Z., Chapman B., Charlebois P., Hofmann O., Weiner B., Porter A.J., Samuel R., Vardhanabhuti S., Zheng L., Eron J., Taiwo B., Zody M.C., Henn M.R., Kuritzkes D.R., Hide W., Wilson C.C., Berzins B.I., Acosta E.P., Bastow B., Kim P.S., Read S.W., Janik J., Meres D.S., Lederman M.M., Mong-Kryspin L., Shaw K.E., Zimmerman L.G., Leavitt R., De La Rosa G., Jennings A. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One 2014, 9:e90485. 10.1371/journal.pone.0090485.
26. Li M., Stoneking M. A new approach for detecting low-level mutations in next-generation sequence data. Genome Biol. 2012, 13:R34. 10.1186/gb-2012-13-345-r.
27. Lohmann V. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113. 10.1126/science.285.5424.110.
28. Macalalad A.R., Zody M.C., Charlebois P., Lennon N.J., Newman R.M., Malboeuf C.M., Ryan E.M., Boutwell C.L., Power K.A., Brackney D.E., Pesko K.N., Levin J.Z., Ebel G.D., Allen T.M., Birren B.W., Henn M.R. Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput. Biol. 2012, 8:e1002417.
29. Malet I., Belnard M., Agut H., Cahour A. From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. J. Virol. Methods 2003, 109:161-170. 10.1016/S0166-0934(03)00067-3.
30. Margulies M., Egholm M., Altman W.E., Attiya S., Bader J.S., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437:376-380. 10.1038/nature03959.
31. Messiaen P., Verhofstede C., Vandenbroucke I., Dinakis S., Van Eygen V., Thys K., Winters B., Aerssens J., Vogelaers D., Stuyver L.J., Vandekerckhove L. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 2012, 426:7-11. 10.1016/j.virol.2012.01.002.
32. Nakamura K., Oshima T., Morimoto T., Ikeda S., Yoshikawa H., Shiwa Y., Ishikawa S., Linak M.C., Hirai A., Takahashi H., Altaf-Ul-Amin M., Ogasawara N., Kanaya S. Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res. 2011, 39:1-13. 10.1093/nar/gkr344.
33. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
34. Nguyen P., Ma J., Pei D., Obert C., Cheng C., Geiger T.L. Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genomics 2011, 12:106. 10.1186/1471-2164-12-106.
35. O'Neil P.K., Sun G., Yu H., Ron Y., Dougherty J.P., Preston B.D., Neil P.K.O. Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J. Biol. Chem. 2002, 277:38053-38061. 10.1074/jbc.M204774200.
36. Palmer S., Kearney M., Maldarelli F., Halvas E.K., Bixby C.J., Bazmi H., Rock D., Falloon J., Davey R.T., Dewar R.L., Metcalf J.A., Hammer S., Mellors J.W., Coffin J.M., Elias K., Julia R.T.D.A. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43:406-413. 10.1128/JCM.43.1.406.
37. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 2006, 299:261-284.
38. Poveda E. Multi-step inhibition against HIV lifecycle-underlying the "magic" of protease inhibitors. AIDS Rev. 2014, 16:52.
39. Prosperi M.C.F., Yin L., Nolan D.J., Lowe A.D., Goodenow M.M., Salemi M. Empirical validation of viral quasispecies assembly algorithms: state-of-the-art and challenges. Sci. Rep. 2013, 3:2837. 10.1038/srep02837.
40. Radford A.D., Chapman D., Dixon L., Chantrey J., Darby A.C., Hall N. Application of next-generation sequencing technologies in virology. J. Gen. Virol. 2012, 93:1-31. 10.1099/vir.0.043182-0.
41. Rodriguez-Frías F., Tabernero D., Quer J., Esteban J.I., Ortega I., Domingo E., Cubero M., Camós S., Ferrer-Costa C., Sánchez A., Jardí R., Schaper M., Homs M., Garcia-Cehic D., Guardia J., Esteban R., Buti M. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One 2012, 7:e37874. 10.1371/journal.pone.0037874.
42. Rozera G., Abbate I., Bruselles A., Vlassi C., Offizi G.D., Narciso P., Chillemi G., Prosperi M., Ippolito G., Capobianchi M.R., D'Offizi G. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15. 10.1186/1742-4690-6-15.
43. Simen B.B., Braverman M.S., Abbate I., Aerssens J., Bidet Y., Bouchez O., Gabriel C., Izopet J., Kessler H.H., Stelzl E., Di Giallonardo F., Schlapbach R., Radonic A., Paredes R., Recordon-Pinson P., Sakwa J., St John E.P., Schmitz-Agheguian G.G., Metzner K.J., Däumer M.P. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. J. Virol. Methods 2014, 204:31-37. 10.1016/j.jviromet.2014.04.007.
44. Simen B.B., Simons F., Hullsiek H., Novak R.M., Macarthur R.D., Baxter J.D., Huang C., Lubeski C., Turenchalk G.S., Braverman M.S., Desany B., Rothberg J.M., Egholm M., Kozal M.J., Beirn T., Programs C., Simons J.F., Hullsiek K.H. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 2009, 199:693-701. 10.1086/596736.
45. Svarovskaia E.S., Martin R., McHutchison J.G., Miller M.D., Mo H. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J. Clin. Microbiol. 2012, 50:3267-3274. 10.1128/JCM.00838-12.
46. Vandenbroucke I., Van Marck H., Verhasselt P., Thys K., Mostmans W., Dumont S., Van Eygen V., Coen K., Tuefferd M., Aerssens J. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 2011, 51:167-177. 10.2144/000113733.
47. Verbinnen T., Marck H., Van Vandenbroucke I., Vijgen L., Claes M., Lin T., Simmen K., Neyts J., Fanning G., Lenz O., Van Marck H. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J. Virol. 2010, 84:11124-11133. 10.1128/JVI.01217-10.
48. Wang C., Mitsuya Y., Gharizadeh B., Ronaghi M., Shafer R.W. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007, 17:1195-1201. 10.1101/gr.6468307.
49. Wei Z., Wang W., Hu P., Lyon G.J., Hakonarson H. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res. 2011, 39:1-13. 10.1093/nar/gkr599.
50. Wilm A., Aw P.P.K., Bertrand D., Yeo G.H.T., Ong S.H., Wong C.H., Khor C.C., Petric R., Hibberd M.L., Nagarajan N. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012, 40:11189-11201. 10.1093/nar/gks918.
51. Yang X., Chockalingam S.P., Aluru S. A survey of error-correction methods for next-generation sequencing. Brief. Bioinform. 2012, 14:56-66. 10.1093/bib/bbs015.
52. Zagordi O., Däumer M., Beisel C., Beerenwinkel N. Read length versus depth of coverage for viral quasispecies reconstruction. PLoS One 2012, 7:e47046. 10.1371/journal.pone.0047046.
53. Zagordi O., Klein R., Däumer M., Beerenwinkel N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 2010, 38:7400-7409. 10.1093/nar/gkq655.